RUBY | Rubius Therapeutics Inc
Category: Consumer goods
Quick infos Headquarters: Massachusetts, United States Trade prices Volume: Market Cap: 132.57M Prev closed: Open: 4.31 High: 4.56 Low: 4.27 52 week low: 4.02 52 week high: 38.71 Dividends: No Dividends Next ER: May 10, 2022 Before Market Opens
Company Profile Rubius Therapeutics developed our proprietary RED PLATFORM® to generate red blood cells and genetically engineer them into a new class of cellular medicines, called Red Cell Therapeutics™ (RCTs). Our RED PLATFORM harnesses both the unique properties of red blood cells and the creative potential of genetic engineering to deliver on the promise of cellular therapy and transform how diseases are treated.
Earnings History Date EPS / Forecast Revenue / Forecast August 16, 2022 May 10, 2022 -0.58 / -0.5717- / -February 25, 2022 -0.61 / -0.585- / -November 8, 2021 -0.55 / -0.5633- / -August 9, 2021 -0.56 / -0.4887- / -view more
Historical Data Date Price Open High Low Vol Change ER May 10, 2022 1.47 1.70 1.70
1.36
1.17M 10.53% May 9, 2022 1.33 1.41 1.45
1.30
702.50K -6.99% May 6, 2022 1.43 1.49 1.55
1.38
853.40K -2.72% May 5, 2022 1.47 1.63 1.66
1.46
453.50K -11.45% May 4, 2022 1.66 1.71 1.71
1.52
886.06K -4.05% May 3, 2022 1.73 1.71 1.78
1.67
694.28K 0% May 2, 2022 1.73 1.65 1.79
1.59
1.16M 4.22% Apr 29, 2022 1.66 1.70 1.76
1.59
808.96K -4.6% Apr 28, 2022 1.74 1.86 1.86
1.56
2.00M -3.33% Apr 27, 2022 1.80 1.71 1.85
1.65
1.76M 2.86% view more
NASDAQ - Nasdaq Stock Market
More profiles and info about the company Founded:2013 Employees:204 News
Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs finance.yahoo.com Feb 28, 2022 9:00 am Rubius Therapeutics GAAP EPS of -$0.61 misses by $0.02 seekingalpha.com Feb 25, 2022 9:08 pm
Rubius Therapeutics Stock Trading Higher On Positive Efficacy, Safety RTX-240 Data In Solid Tumor Study finance.yahoo.com Feb 19, 2022 2:06 pm Rubius Doubles on Progress in Early-Stage Cancer-Drug Trial thestreet.com Feb 19, 2022 9:14 am
Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening finance.yahoo.com Feb 19, 2022 9:01 am
Company News for Mar 16, 2021 finance.yahoo.com Feb 19, 2022 8:50 am Rubius Therapeutics begins dosing in phase 1/2 trial of RTX-224 for solid tumors seekingalpha.com Jan 13, 2022 10:25 pm Rubius to report additional Phase 1 data for RTX-240 in solid tumors next quarter seekingalpha.com Dec 16, 2021 10:13 pm
Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive Cancers finance.yahoo.com Feb 19, 2022 8:00 am
Rubius Therapeutics: Promising Cancer Treatment Data De-Risks Pipeline finance.yahoo.com Feb 19, 2022 1:15 am
INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT finance.yahoo.com Feb 15, 2022 10:05 am
Rubius Therapeutics to Present at the Virtual Guggenheim Healthcare Talks and SVB Leerink Global Healthcare Conference in February 2022 finance.yahoo.com Feb 1, 2022 8:00 am
Rubius Therapeutics Recaps 2021 Achievements and Outlines 2022 Objectives Across the RED PLATFORM at the 40th Annual J.P. Morgan Healthcare Conference finance.yahoo.com Jan 10, 2022 8:00 am
Rubius Therapeutics to Highlight the Power of its RED PLATFORM®, Significant Advances Across Red Cell Therapeutic Oncology Pipeline and New Type 1 Diabetes Program at Platform and Pipeline Day finance.yahoo.com Dec 16, 2021 8:00 am Catalyst watch for next week: FOMC drama, events for Lowe's and Delta Air Lines, Rivian earnings seekingalpha.com Dec 11, 2021 4:00 am
Rubius Therapeutics to Host Virtual Preclinical Pipeline and Platform Technology Day on December 16, 2021 finance.yahoo.com Dec 1, 2021 4:15 pm
Rubius Therapeutics Presents Preclinical Data for RTX-224, a Broad Immune Costimulatory Agonist, at the Society for Immunotherapy of Cancers Annual Meeting finance.yahoo.com Nov 12, 2021 7:00 am Rubius Therapeutics EPS beats by $0.02 seekingalpha.com Nov 9, 2021 5:37 am
Rubius Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update finance.yahoo.com Nov 8, 2021 4:15 pm
Rubius Therapeutics to Announce Third Quarter 2021 Financial Results finance.yahoo.com Oct 28, 2021 9:00 am This company doesn't provide a dividend.
Key Persons Talk about Rubius Therapeutics Inc below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature. Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
Consensus BUY 50 HOLD 50 SELL 0
If you want to help pay for server cost or for improving this tool. You can send it via Paypal . More features coming soon :)
Buy on Amazon Technical analysis is a collection of techniques designed to help you make trading decisions in securities markets. Technical Analysis For Dummies helps you take a hard-headed look at what securities prices are actually doing rather than what economists or analysts say they should be doing, giving you the know-how to use that data to decide whether to buy or sell individual securities.
A simple, straightforward guide to the fundamentals of technical analysis